Cite
Long-term effects of lanreotide SR and octreotide LAR® on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly.
MLA
Amato, Giovanni, et al. “Long-Term Effects of Lanreotide SR and Octreotide LAR® on Tumour Shrinkage and GH Hypersecretion in Patients with Previously Untreated Acromegaly.” Clinical Endocrinology, vol. 56, no. 1, Jan. 2002, pp. 65–71. EBSCOhost, https://doi.org/10.1046/j.0300-0664.2001.01438.x.
APA
Amato, G., Mazziotti, G., Rotondi, M., Iorio, S., Doga, M., Sorvillo, F., Manganella, G., Di Salle, F., Giustina, A., & Carella, C. (2002). Long-term effects of lanreotide SR and octreotide LAR® on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly. Clinical Endocrinology, 56(1), 65–71. https://doi.org/10.1046/j.0300-0664.2001.01438.x
Chicago
Amato, Giovanni, Gherardo Mazziotti, Mario Rotondi, Sergio Iorio, Mauro Doga, Francesca Sorvillo, Giovanni Manganella, Francesco Di Salle, Andrea Giustina, and Carlo Carella. 2002. “Long-Term Effects of Lanreotide SR and Octreotide LAR® on Tumour Shrinkage and GH Hypersecretion in Patients with Previously Untreated Acromegaly.” Clinical Endocrinology 56 (1): 65–71. doi:10.1046/j.0300-0664.2001.01438.x.